U.S. Markets open in 5 hrs 20 mins

CLASS ACTION UPDATE for CVS, SRPT and DBX: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders

NEW YORK, NY / ACCESSWIRE / October 10, 2019 / Levi & Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies. To determine your eligibility and get free access to our shareholder support tools that provide you with case updates, automated loss calculations and claims recovery assistance, please contact the firm via the links below. There will be no cost or obligation to you.

CVS Health Corporation (CVS)

Lawsuit on behalf of: investors who purchased on behalf of all former Aetna Inc. shareholders who acquired CVS Health Corporation (CVS) shares in exchange for their Aetna shares in connection with CVS's acquisition of Aetna on November 28, 2018.
Lead Plaintiff Deadline : October 15, 2019
TO LEARN MORE, VISIT: https://www.zlk.com/pslra-1/cvs-health-corporation-loss-form-2?prid=3893&wire=1

According to the filed complaint, CVS made false and/or misleading statements in connection with its acquisition of Aetna and/or failed to disclose that: (a) by the end of 2017, CVS's financial condition and expected earnings had deteriorated as a result of rising costs and poor results being experienced in the long-term care ("LTC") unit associated with the 2015 acquisition of Omnicare; (b) in 2017, deteriorating conditions and prospects in CVS 's LTC unit prompted CVS to undertake hasty acquisitions of LTC pharmacies to compensate for the declining LTC business and/or mask the expected LTC goodwill impairment ahead of the planned Acquisition; (c) although negative LTC performance factors prompted CVS and the CVS Individual Defendants to make hasty LTC pharmacy acquisitions in 2017, those same negative factors were being overlooked and ignored for purposes of undertaking, disclosing, and reporting the results of LTC goodwill impairment tests throughout 2017, in violation of GAAP; (d) the LTC goodwill being carried on CVS's books as a result of the Omnicare acquisition was being carried at inflated values that would require billions of dollars in impairment charges that would be charged against earnings; and (e) as a result of the foregoing, CVS's true business metrics and financial prospects were not as the Offering Documents represented.

Sarepta Therapeutics, Inc. (SRPT)

Lawsuit on behalf of: investors who purchased September 6, 2017 - August 19, 2019
Lead Plaintiff Deadline : October 29, 2019
TO LEARN MORE, VISIT: https://www.zlk.com/pslra-1/sarepta-therapeutics-inc-loss-form?prid=3893&wire=1

According to the filed complaint, during the class period, Sarepta Therapeutics, Inc. made materially false and/or misleading statements and/or failed to disclose that: (i) golodirsen, Sarepta's drug for the treatment of Duchenne muscular dystrophy, posed significant safety risks to patients; (ii) consequently, the New Drug Application package for golodirsen's accelerated approval was unlikely to receive Food and Drug Administration approval; and (iii) as a result, Sarepta's public statements were materially false and misleading at all relevant times.

Dropbox, Inc. (DBX)

Lawsuit on behalf of: investors who purchased on behalf of all persons who purchased Dropbox Class A common stock pursuant or traceable to the registration statement issued in connection with the Company's March 23, 2018 initial public offering.
Lead Plaintiff Deadline : December 3, 2019
TO LEARN MORE, VISIT: https://www.zlk.com/pslra-1/dropbox-inc-loss-form?prid=3893&wire=1

According to the filed complaint, (1) Dropbox had materially overstated its ability to monetize its user base; (2) Dropbox was facing worsening revenue trends, which were negatively impacting the Company at the time of the initial public offering ("IPO"); (3) Dropbox was tracking below its internal revenue and monetization targets at the time of the IPO; and (4) as a result, defendants' statements about Dropbox's business, operations, and prospects were materially false and misleading and/or lacked a reasonable basis at all relevant times.

You have until the lead plaintiff deadlines to request that the court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.

Levi & Korsinsky is a national firm with offices in New York, California, Connecticut, and Washington D.C. The firm's attorneys have extensive expertise and experience representing investors in securities litigation and have recovered hundreds of millions of dollars for aggrieved shareholders. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:
Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
55 Broadway, 10th Floor
New York, NY 10006
jlevi@levikorsinsky.com
Tel: (212) 363-7500
Fax: (212) 363-7171
www.zlk.com

SOURCE: Levi & Korsinsky, LLP



View source version on accesswire.com:
https://www.accesswire.com/562710/CLASS-ACTION-UPDATE-for-CVS-SRPT-and-DBX-Levi-Korsinsky-LLP-Reminds-Investors-of-Class-Actions-on-Behalf-of-Shareholders